Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folic acid into its active form. By inhibiting this step, the drug reduces the synthesis of purine nucleotides and thymidylate, leading to decreased DNA, RNA and protein production. This effect is most pronounced in rapidly dividing cells, such as immune cells and malignant tumor cells, thereby reducing inflammation and tumor growth.

The dose of Metoject is individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal and hepatic function, and response to therapy. Because dosing varies widely across conditions—from low weekly doses for rheumatoid arthritis to higher, intermittent doses for oncology protocols—the prescriber sets the exact regimen and monitors the patient closely.

Metoject is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and embryotoxicity. It should not be used by women who are pregnant or planning to become pregnant. Breastfeeding is also discouraged because methotrexate can be excreted in breast milk and may harm the infant.

To request Metoject, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details—including cold‑chain handling if needed—and assist with any required import documentation.

Metoject (methotrexate) is one of the most widely used antimetabolites, distinguished by its oral and injectable formulations and a broad therapeutic spectrum that includes both autoimmune diseases and cancers. Compared with newer agents such as pemetrexed or leflunomide, methotrexate has a longer safety record but may require more intensive monitoring for hepatic and hematologic toxicity. Choice of therapy depends on disease type, patient factors and clinician experience.

Metoject should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product must be transported, use validated cold‑chain containers to maintain the temperature range throughout the journey.

Metoject is supplied as a sterile injection that can be given intramuscularly, intravenously, or subcutaneously, depending on the clinical indication and physician preference. The route, volume and rate of administration are determined by the prescriber. In oncology settings, the injection is often given as a short infusion, whereas for rheumatic diseases it may be administered as a quick intramuscular or subcutaneous injection.

The most serious risks include severe liver toxicity, which can progress to hepatitis or cirrhosis; pulmonary complications such as interstitial pneumonitis or fibrosis; profound bone‑marrow suppression leading to pancytopenia; and life‑threatening infections due to immunosuppression. Renal failure and rare cutaneous necrosis are also reported. Patients should be monitored regularly for early signs of these complications.

Metoject is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate or any component of the formulation, and patients with severe hepatic or renal impairment that cannot be corrected. It should also be avoided in patients receiving live vaccines or those with uncontrolled infections. Clinicians must evaluate each patient’s medical history before initiating therapy.